Literature DB >> 14622077

Brain lesion volume and neuropsychological function predict efficacy of treatment for depression in multiple sclerosis.

David C Mohr1, Lucy Epstein, Tracy L Luks, Donald Goodkin, Darcy Cox, Alison Goldberg, Cynthia Chin, Sarah Nelson.   

Abstract

This study examined the effects of brain lesions and neuropsychological impairment on the efficacy of treatment for depression in patients with comorbid diagnoses of multiple sclerosis (MS) and major depressive disorder (MDD). Thirty patients meeting criteria for MS and MDD received 1 of 3 16-week treatments for depression and were followed for 6 months following treatment cessation. T2-weighted magnetic resonance imaging and neuropsychological evaluations were also obtained. End-of-treatment Beck Depression Inventory (BDI; A. T. Beck, C. H. Ward, M. Mendelson, J. Mock, & J. Erbaugh, 1961) results residualized for baseline BDI were related to right temporal periventricular lesion volume (R2=.32, p=.002) and left temporal grey-white junction lesion volume (R2=.19, p=.02) but were not statistically related to lesion volume in any other brain region or to neuropsychological function. BDI results at 6-month follow-up, residualized for end-of-treatment BDI, were predicted by total lesion volume (R2=.22, p=.005), lesion volume in many discrete areas, and neuropsychological functioning (R2=.29, p=.0009). The effect of total lesion volume on 6-month follow-up BDI results was fully mediated by neuropsychological function. (c) 2003 APA

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14622077     DOI: 10.1037/0022-006X.71.6.1017

Source DB:  PubMed          Journal:  J Consult Clin Psychol        ISSN: 0022-006X


  6 in total

1.  Domain-specific impairment in cognitive control among remitted youth with a history of major depression.

Authors:  Amy T Peters; Rachel H Jacobs; Natania A Crane; Kelly A Ryan; Sara L Weisenbach; Olusola Ajilore; Melissa Lamar; Michelle T Kassel; Laura B Gabriel; Amy E West; Jon-Kar Zubieta; Scott A Langenecker
Journal:  Early Interv Psychiatry       Date:  2015-07-14       Impact factor: 2.732

Review 2.  The link between multiple sclerosis and depression.

Authors:  Anthony Feinstein; Sandra Magalhaes; Jean-Francois Richard; Blair Audet; Craig Moore
Journal:  Nat Rev Neurol       Date:  2014-08-12       Impact factor: 42.937

3.  A randomized trial of stress management for the prevention of new brain lesions in MS.

Authors:  David C Mohr; Jesus Lovera; Ted Brown; Bruce Cohen; Thomas Neylan; Roland Henry; Juned Siddique; Ling Jin; David Daikh; Daniel Pelletier
Journal:  Neurology       Date:  2012-07-11       Impact factor: 9.910

4.  Frontal and limbic activation during inhibitory control predicts treatment response in major depressive disorder.

Authors:  Scott A Langenecker; Susan E Kennedy; Leslie M Guidotti; Emily M Briceno; Lawrence S Own; Thomas Hooven; Elizabeth A Young; Huda Akil; Douglas C Noll; Jon-Kar Zubieta
Journal:  Biol Psychiatry       Date:  2007-06-21       Impact factor: 13.382

Review 5.  Depression in Multiple Sclerosis: Epidemiology, Aetiology, Diagnosis and Treatment.

Authors:  Claudio Solaro; Giulia Gamberini; Fabio Giuseppe Masuccio
Journal:  CNS Drugs       Date:  2018-02       Impact factor: 5.749

6.  Cognitive-constructivist Approach in Medical Settings: The Use of Personal Meaning Questionnaire for Neurological Patients' Personality Investigation.

Authors:  Barbara Poletti; Laura Carelli; Annalisa Lafronza; Federica Solca; Andrea Faini; Andrea Ciammola; Monica Grobberio; Vanessa Raimondi; Rita Pezzati; Rita B Ardito; Vincenzo Silani
Journal:  Front Psychol       Date:  2017-04-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.